Streetbeat News

Products Services

NVO

A recent study published in JAMA has raised concerns about the potential risks associated with popular weight loss and diabetes drugs like Novo Nordisk's Wegovy, Ozempic, and Saxenda. The study suggests that these drugs may be linked to three rare but severe stomach conditions in non-diabetic patients. The FDA has updated the labeling for Novo Nordisk's Ozempic to include warnings about reported blocked intestines following its use.

Portfolio Pulse from Vandana Singh

October 06, 2023 | 1:03 pm

BON

Bon Natural Life Limited (NASDAQ:BON) has signed a Memorandum of Understanding with Guangdong Jiangwang International Holdings Limited to negotiate terms for distributing Jiangwang's spirits and related health products in China. This marks BON's first entry into the spirits industry, leveraging its R&D strength in spirit-related health food.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 1:03 pm

AMGN

MRTX

FDA advisers have expressed doubts about the reliability of data from a late-stage trial of Amgen Inc's Lumakras for advanced lung cancer, voting 10 'no' to 2 'yes' for traditional approval. The drug had initially received FDA approval in 2021 through an accelerated pathway, contingent on confirmatory trial data. The confirmatory study data revealed that Lumakras reduced the risk of disease progression in patients with advanced lung cancer by 34% compared to chemotherapy. A decision from the FDA on traditional approval is expected by December 24.

Portfolio Pulse from Vandana Singh

October 06, 2023 | 12:59 pm

CRWD

FTV

PXD

XOM

On CNBC's 'Halftime Report Final Trades', ExxonMobil Corporation was mentioned for its 3.2% dividend yield and share buyback. ExxonMobil is reportedly acquiring Pioneer Natural Resources Co. for approximately $60 billion. Fortive Corporation was named by Karen Firestone of Aureus Asset Management, highlighting its Q2 sales growth of 4.3% YoY. Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc., which recently launched cybersecurity's first zero-code application development platform.

Portfolio Pulse from Priya Nigam

October 06, 2023 | 12:55 pm

GM

GOOGL

TSLA

Dan O'Dowd, CEO of Green Hills Software and founder of the Dawn Project, criticized Tesla's Full Self-Driving (FSD) software in an interview with Benzinga. He called the FSD 'terrible' and stated that it could be banned. O'Dowd's team found flaws in Tesla's driver monitoring system and compared Tesla's FSD unfavorably with General Motors' Cruise and Alphabet's Waymo. He also accused Elon Musk of coordinating online attacks against him. Ark Investment Management CEO Cathie Wood and Future Fund’s Gary Black, however, expressed optimism about Tesla's FSD.

Portfolio Pulse from Anan Ashraf

October 06, 2023 | 12:50 pm

TSLA

Tesla has reduced the prices of its Model Y and 3 vehicles in the U.S., leading to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:38 pm

FOXO

FOXO Technologies' Interim CEO, Mark White, has outlined a new strategy for the company, focusing on AI-enabled direct-to-consumer services and immediate expense reductions. The company plans to launch a subscription-based app leveraging AI, machine learning, and epigenetic data to enhance health and wellness. FOXO is also considering strategic alternatives, including the acquisition of complementary AI technologies and/or strategic sales of assets. The company is shifting its focus away from selling life insurance products and instead concentrating on its Bioinformatics Services offering.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:34 pm

SHEL

Shell PLC has revised its Q3 FY23 operational outlook. The company updated the production outlook for Integrated Gas and LNG liquefaction volumes, reflecting scheduled maintenance. Shell also narrowed production guidance for Upstream and lowered the higher end of the sales volume guidance for marketing. The company currently sees refinery utilization of 82% - 86% and Chemicals utilization of 68% - 72%. Shell projects Q3 chemicals sub-segment adjusted earnings to align with Q2 FY23. The company expects to release Q3 FY23 results on November 2, 2023.

Portfolio Pulse from Lekha Gupta

October 06, 2023 | 12:28 pm

JNJ

Johnson & Johnson's Janssen has submitted a supplemental marketing application to the European Medicines Agency for Rybrevant (Amivantamab) in combination with chemotherapy for advanced non-small cell lung cancer with EGFR Exon 20 insertion mutations.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:13 pm

MTEK

Maris-Tech has launched a new AI-powered video analytics product, the Jupiter Drones, for the unmanned aerial vehicle market. The product is versatile and can be tailored to multiple camera configurations.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:12 pm